Television coverage of AIDS and transmission of the AIDS virus

The introduction of the government framework “The national strategy for sexual health and HIV” is necessary for attempts to prevent sexual causes of premature death and ill health, at a time when transmission of HIV is at a record level and heterosexual intercourse is the most commonly reported mode of transmission. However, policy formation alone will not be effective in the fight against AIDS in the United Kingdom. Commentators have noted television coverage of AIDS has declined as transmission of HIV continues. Thirty seven UK terrestrial programmes covering HIV/AIDS were identified, the earliest in 1983, most recent in 2000, and a peak of programmes in the late 1980s. Between 1996 and 1999 no programmes covering HIV/AIDS were found.

The findings of my study are tentative, but hint that television coverage of AIDS has declined as transmission of HIV continues. This complements Nicoll and colleagues’ argument that AIDS campaigns (often televised) are likely to have reduced HIV transmission in the 1980s. Television is a rich source of information about AIDS, offering a powerful while unvaluated medium for promoting AIDS awareness and safer sex to the general public. Given the current low level of media interest and the ceaseless increase of HIV transmission, it may be beneficial to formally evaluate a national media campaign on this important public health issue using quasi-experimental methods.

High frequency of antibodies to syphilis and HIV in hepatitis C virus positive blood donors may reflect its sexual transmission in this region

Hepatitis C virus (HCV) infection is a great cause of concern because of the risk of chronicity and other sequelae. Studies on prevalence behaviour pattern and sexual transmission of HCV infection among the population are required for formulating strategies to control spread of HCV. The aim of this study was to evaluate the occurrence of HCV in voluntary blood donors as they are known to be a high risk population for transmission of these infections. Comparison was made between the presence of syphilis, HIV, and HCV infection in HCV negative and positive blood donors to confirm these as markers or predictors of HIV infection in a high risk population which may reflect the transmission of HCV by a sexual route.

Voluntary blood donors (n = 3905) from New Delhi, India, were randomly recruited between August 2001 to March 2002 and were unpaid. These donors were screened for antibodies to VDRL, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), and HIV using previously validated second generation ELISA kits. Data were analysed using the χ² test. Odds ratio (OR) was used to measure strength of an association.

References
2 Jackson T. No news is bad news. BMJ 2000;321:1419
4 Garfield S. The end of innocence: Britain in the time of AIDS. London: Faber and Faber, 1995

Accepted for publication 17 October 2002

www.stijournal.com
The antibodies to HCV were detected in 61 (1.56%), HBsAg in 109 (2.79%), VDRL in 132 (3.38%), and HIV in 40 (1.02%) donors. In HCV negative blood donors, VDRL was detected in 129 (3.35%), HBsAg in 106 (2.73%) and HIV in 31 (0.8%) donors, while in HCV positive blood donors HIV positivity increased significantly to nine (14.75%) OR (21.2) and VDRL and HBsAg reactivity increased to three (4.91%) (OR 1.82 and 1.48 respectively). Thus HIV, VDRL, and HBsAg reactivity was found 21.2, 1.48, and 1.82 times more often respectively in HCV positive blood donors (table 1).

In conclusion, the high frequency of antibodies to syphilis and HIV in HCV positive blood donors may confirm this as a marker or predictor of HIV infection in a high risk population and may also reflect the risk of transmission of HCV by the sexual route, which seems to vary with the population studied.

A Mittal
Institute of Pathology (ICMR), Post Box No 4909, Safdarjung Hospital Campus, New Delhi-110029, India; amittal_iap@yahoo.com

References

Accepted for publication 30 October 2002

Self obtained samples for genitourinary infections

We assessed the concept of self sampling, as part of screening for sexually transmitted diseases, first in the early 1990s in a pilot study. The aim was to assess the validity and acceptability of the procedure as an alternative for the sex industry workers (or as a supplementary method between attendances), for those who are reluctant or unable to attend GUM clinics frequently. Microbiological techniques were not as developed or as sensitive as today’s (PCR) tests. Since then, other studies reported on the feasibility and acceptability of self obtained samples.1

We read with interest, the article published in STI regarding the diagnosis of chlamydia, gonorrhoea and trichomona infections by self obtained low vaginal swabs. The techniques employed in the Australian study (patients obtaining swabs while sitting or squatting) would allow less access to the genital tract than our originally proposed squatting positions. In our study, the patient was advised first by a female nurse on the squatting position and locating the cervix. She was re-advised on repeating the procedure and the attempt to take the swabs from the cervical surface. In our study, 86.7% of patients reported their ability to access the cervix (and, therefore, obtain high vaginal/cervical samples). The squatting position has the advantage of providing patients with the freedom to use both hands (one of which may be used to open the vulval lips). The technique is similar to that employed by women for self examination before the insertion of a cervical cap or for a vagi (VY) or intrauterine contraceptive device threads.

The new methods of information technology, with their declining cost, can provide extra support to the concept of self obtained samples with high and better access to their results. The result of the tests may then be obtained by the patient by telephone (possibly via an automated service or a text message, using an identical telephone number). The procedure is already in use by the banking services for accessing personal and confidential information. It is possible to provide the sampling materials in a “test pack” that may be returned to a central laboratory, by post. The pack may include information and explanatory notes and a coded identification number. This would help to identify the patient’s samples, with confidentiality.

The recent escalation in the incidence of sexually transmitted infections, coupled with the increasing workload for GUM clinics is representing a challenge for adopting new ways in combating the spread of sexually transmitted infections. The exploitation of new ideas, methods, and technologies could be of benefit, especially in areas out of access to advanced laboratory investigations (remote and rural areas). It could also be used as a supplementary method to current medical care (between visits) in special patient groups (for example, adolescents1 and sex industry workers).2

A R Markos
Staffordshire General Hospital, Weston Road, Stafford ST16 3SA, UK; stephien.thorpe@msgh-tr.wmids.nhs.uk

References

A survey of STI policies and programmes in Europe

The survey by Dehne et al was carried out in 1998-9 and inevitably does not necessarily represent the current situation.3 The authors report that the United Kingdom has no national STI programme and management guidelines. The first ever national strategy for sexual health and HIV for England was published in 2001.4 It contains the two key objectives of ensuring that everyone has better access to information on sexual health and to make services more available and accessible to all those who require them at all ages. The strategy also has specific aims of reducing acquisition, transmission and the prevalence of undiagnosed HIV and STIs. Specific targets to increase the uptake of HIV testing in hepatitis B vaccination have also been set.

The issue of case management guidelines was not detailed in the strategy since this has been specifically tackled by the specialty of genitourinary medicine. A clinical effectiveness group was set up between the Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases in 1997, with the specific remit of producing evidence based national guidelines and standards for those working in the specialty of genitourinary medicine. These were published in STI in 19995 and updated in 2002.6

I hope these observations will help to update the survey with particular reference to England.

M W Adler
Department of Sexually Transmitted Diseases, Royal Free and University College Medical School, The Mortimer Market Centre, Off Capper Street, London WC1E 6AU, UK; m.w.adler@gum.ucl.ac.uk

References

Accepted for publication 29 November 2002

Polymorphic immune restoration syndrome after effective HAART

HAART is able to suppress HIV replication and restore specific immune responses. We and others’ have demonstrated that previously

Table 1 Percentage positivity of HBsAg, VDRL, and HIV in HCV positive and negative blood donors

<table>
<thead>
<tr>
<th>HCV +ve (n=61)</th>
<th>HCV -ve (n=3844)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg (%)</td>
<td>3 (4.91)</td>
<td>106 (2.75)</td>
</tr>
<tr>
<td>VDRL (%)</td>
<td>3 (4.91)</td>
<td>129 (3.35)</td>
</tr>
<tr>
<td>HIV (%)</td>
<td>9 (14.75)</td>
<td>31 (0.80)</td>
</tr>
</tbody>
</table>

χ²=122.8, p<0.001.


Accepted for publication 30 October 2002
untreatable progressive multifocal leukoencephalopathy (PML) may improve and has very rarely been reported following HAART. However, CD4+ increase is also associated with inflammatory reactions to previously silent infectious agents, as well as aberrant immune phenomena.

Case report
A 27 year old HIV/HCV (hepatitis C virus) patient was observed in 1997 with a CD4+ count of 357 cells/µl and HIV-RNA >100 000 copies/ml. HAART was started and maintained until 1999 when it was stopped at the patient’s request. On October 2001 he returned asymptomatic, with a CD4+ cell count of 34 ×10⁹/l and HIV-RNA 130 000 copies/ml. Stavudine + lamivudine + nevirapine were then started, together with trimethoprim-sulfamethoxazole. He experienced an optimal response (CD4+ count 159 ×10⁹/l, HIV-RNA <50 copies/ml) combined with the first case of liver damage related to delayed immune mediated hypersensitivity reaction to nevirapine. Several facts support an immunopathogenic role of aberrant immune recovery in this case: (i) these phenomena occurred together in concomitance with raising CD4+ T cell count under effective HAART; (ii) PML during HAART is exceptional; (iii) both PML during HAART and nevirapine hypersensitivity* occurred during the first weeks of therapy in the case series reported so far; (iv) nevirapine hypersensitivity is frequent in conditions of preserved immune response.* This underlines that pathogenic mechanisms and immunological factors associated with immune restoration diseases may be diverse and unexpected. Moreover, nevirapine hypersensitivity is immediate while this case of liver damage occurred after a substantial period on nevirapine and with concomitant elevation of γ-GT enzyme and increase in HCV replication. Therefore, it would have been very difficult to make the correct differential diagnosis with either late onset metabolic idiosyncrasy to nevirapine or relapsing HCV hepatitis without liver histology. Thus, avoiding liver biopsy in such cases may lead to an underestimation of the causative role of nevirapine.

References

NOTICES
International Herpes Alliance and International Herpes Management Forum
The International Herpes Alliance has introduced a web site (www.herpesalliance.org) where patient information leaflets can be downloaded. Its sister organisation the International Herpes Management Forum (web site: www.IHMF.org) has launched new guidelines on the management of herpesvirus infections in pregnancy at the 9th International Congress on Infectious Disease (ICID) in Buenos Aires.

Pan-American Health Organization, regional office of the World Health Organization
A catalogue of publications is available online (www.paho.org). The monthly journal of PAHO, the Pan American Journal of Public Health, is also available (subscriptions: pubsvc@tps.sheridan.com).

XIX International Congress of the Society of The Fetus as a Patient
1–4 May 2003, Gran Hotel Sitges, Barcelona, Sitges, Spain. Further details: (fax: +34 93 418 7832; email: bcn2003@tudexeu.es).

Australasian Sexual Health Conference: Tango down South—2003!

NSC Dermatology Update 2003
27–29 June 2003, Singapore. Further details: Mrs. Alice Chew, National Skin Centre, 1 Mandalay Road, Singapore 308205 (tel: +65 6350 8405; fax: +65 6253 3225; email: training@nsc.gov.sg).